AR090865A1 - Forma farmaceutica oral para la prevencion de enfermedades vasculares, comprimido como forma farmaceutica y capsula de gelatina como forma farmaceutica - Google Patents

Forma farmaceutica oral para la prevencion de enfermedades vasculares, comprimido como forma farmaceutica y capsula de gelatina como forma farmaceutica

Info

Publication number
AR090865A1
AR090865A1 ARP130101424A ARP130101424A AR090865A1 AR 090865 A1 AR090865 A1 AR 090865A1 AR P130101424 A ARP130101424 A AR P130101424A AR P130101424 A ARP130101424 A AR P130101424A AR 090865 A1 AR090865 A1 AR 090865A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical form
prevention
acceptable salts
compressed
pharmacologically acceptable
Prior art date
Application number
ARP130101424A
Other languages
English (en)
Inventor
Magalhes Lahmann Walker
Oliveira Dos Santos Filho Hilton
Renno Dos Mares Guia Thiago
Campos Junior Aguinaldo
Original Assignee
Hypermarcas S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypermarcas S A filed Critical Hypermarcas S A
Publication of AR090865A1 publication Critical patent/AR090865A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formas farmacéuticas orales, destinadas al uso terapéutico en la prevención de enfermedades cardio y cerebrovasculares en mamíferos, preferentemente en humanos. De forma particular la presente se refiere a un comprimido que comprende (a) uno o más inhibidores de HMG-CoA reductasa, (b) uno o más antagonistas de receptores de angiotensina II y (c) uno o más diuréticos de la clase de las tiazidas, en donde (a) no está en contacto físico con (b) ó (c). Reivindicación 3: Forma farmacéutica de acuerdo con la reivindicación 1 caracterizada porque (a) uno o más inhibidores de HMG-CoA reductasa son estatinas o sus sales farmacológicamente aceptables, estabilizadas con agentes alcalinizantes. Reivindicación 6: Forma farmacéutica de acuerdo con la reivindicación 3 caracterizada porque la estatina es atorvastatina o sus sales farmacológicamente aceptables en formas cristalina o amorfa. Reivindicación 8: Forma farmacéutica de acuerdo con la reivindicación 7 caracterizada porque el antagonista de los receptores de angiotensina II es losartán o sus sales farmacológicamente aceptables.
ARP130101424A 2012-04-26 2013-04-26 Forma farmaceutica oral para la prevencion de enfermedades vasculares, comprimido como forma farmaceutica y capsula de gelatina como forma farmaceutica AR090865A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102012009735-4A BR102012009735A2 (pt) 2012-04-26 2012-04-26 Forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica

Publications (1)

Publication Number Publication Date
AR090865A1 true AR090865A1 (es) 2014-12-10

Family

ID=49482044

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101424A AR090865A1 (es) 2012-04-26 2013-04-26 Forma farmaceutica oral para la prevencion de enfermedades vasculares, comprimido como forma farmaceutica y capsula de gelatina como forma farmaceutica

Country Status (4)

Country Link
AR (1) AR090865A1 (es)
BR (1) BR102012009735A2 (es)
UY (1) UY34769A (es)
WO (1) WO2013159166A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102013028883A2 (pt) * 2013-11-08 2015-10-06 Hypermarcas S A forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070123498A1 (en) * 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
GB2482432B (en) * 2009-02-11 2013-09-11 Cadila Pharmaceuticals Ltd Stable pharmaceutical composition for atherosclerosis

Also Published As

Publication number Publication date
BR102012009735A2 (pt) 2014-04-15
WO2013159166A1 (pt) 2013-10-31
UY34769A (es) 2013-11-29

Similar Documents

Publication Publication Date Title
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
CL2012003178A1 (es) Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia.
CY1125290T1 (el) Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
CY1120939T1 (el) Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου
CR20150371A (es) Inhibidores de prmt5 y sus usos
CR20120419A (es) Formulación de anticuerpos y regimenes terapéuticos
ECSP15022555A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
NI201400108A (es) Compuestos de heterociclilo
CL2013001772A1 (es) Compuestos derivados de indol y azaindol, como inhibidores de la faah; composicion farmaceutica que los comprende, util para el tratamiento o prevencion del dolor, trastornos autoinmunes, procesos inflamatorios, enfermedades gastrointestinales, prurito, enfermedad relacionada con abuso de sustancias, entre otras enfermedades.
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
CL2013002341A1 (es) Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CR20140513A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CY1110097T1 (el) Διπλοστοιβαδικο δισκιο για προληψη καρδιαγγειακων συμβαντων
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
CU20130139A7 (es) Derivados glocósidos y usos de los mismos
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
CR20150267A (es) 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il] 1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como un antagonista del receptor ampa dependiente de tarp-gamma 8
UY35209A (es) Compuestos tricíclicos
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
UY35211A (es) Compuestos tricíclicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure